Abvc Biopharma (ABVC) Current Deferred Revenue (2022 - 2026)
Abvc Biopharma's (ABVC) quarterly Current Deferred Revenue came in at $12600.0 in Q1 2026, down 84.47% YoY from $81115.0 in Q1 2025, and little changed on a QoQ basis from $12600.0 in Q4 2025.
Abvc Biopharma (ABVC) Current Deferred Revenue (2022 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 5 years of Current Deferred Revenue data on file, last reported at $12600.0 in Q1 2026.
- Quarterly Current Deferred Revenue fell 84.47% year-over-year to $12600.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12600.0 (down 84.47% YoY) and the FY2025 annual result came in at $12600.0, down 84.47% from the prior year.
- Current Deferred Revenue steadied at $12600.0 in Q1 2026, from $12600.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $81115.0 in Q4 2024 to a low of $10985.0 in Q4 2022.
- A 5-year average of $64434.4 and a median of $79500.0 in 2023 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2023 — Current Deferred Revenue jumped 623.71% — and 2025, when it sank 84.47%.
- Tracing ABVC's Current Deferred Revenue over 5 years: stood at $10985.0 in 2022, then jumped by 623.71% to $79500.0 in 2023, then increased by 2.03% to $81115.0 in 2024, then slumped by 84.47% to $12600.0 in 2025, then changed by 0.0% to $12600.0 in 2026.
- The last three Current Deferred Revenue figures came in at $12600.0 (Q1 2026), $12600.0 (Q4 2025), and $81115.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - |
| 10 | Abvc Biopharma | 22.93 Mn | 22.93 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12,600.00 |
| Mar 31, 2026 | 12,600.00 |
| Dec 31, 2025 | 12,600.00 |
| Sep 30, 2025 | 81,115.00 |
| Jun 30, 2025 | 81,115.00 |
| Mar 31, 2025 | 81,115.00 |
| Dec 31, 2024 | 81,115.00 |
| Sep 30, 2024 | 79,500.00 |
| Jun 30, 2024 | 79,500.00 |
| Mar 31, 2024 | 79,500.00 |
| Dec 31, 2023 | 79,500.00 |
| Sep 30, 2023 | 79,501.00 |
| Jun 30, 2023 | 79,501.00 |
| Dec 31, 2022 | 10,985.00 |